DK1109558T3 - Ranolazinformuleringer med langvarig frigivelse - Google Patents

Ranolazinformuleringer med langvarig frigivelse

Info

Publication number: DK1109558T3
Authority: DK; Denmark
Prior art keywords: sustained release; release formulations; ranolazine sustained; ranolazine; formulations
Prior art date: 1998-09-10

Application number

DK99968627T

Other languages

Danish (da)

English (en)

Inventor

Andrew A Wolff

Fiona Baker

John Langridge

Original Assignee

Cv Therapeutics Inc

Syntex Inc

Syntex Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-10

Filing date

1999-09-09

Publication date

2002-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1109558(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-09 Application filed by Cv Therapeutics Inc, Syntex Inc, Syntex Llc filed Critical Cv Therapeutics Inc

2002-08-26 Application granted granted Critical

2002-08-26 Publication of DK1109558T3 publication Critical patent/DK1109558T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

DK99968627T 1998-09-10 1999-09-09 Ranolazinformuleringer med langvarig frigivelse DK1109558T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9980498P	1998-09-10	1998-09-10
US09/321,522 US6303607B1 (en)	1998-09-10	1999-05-27	Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020967 WO2000013686A2 (en)	1998-09-10	1999-09-09	Sustained release ranolazine formulations

Publications (1)

Publication Number	Publication Date
DK1109558T3 true DK1109558T3 (da)	2002-08-26

Family

ID=26796494

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK99948196T DK1096937T3 (da)	1998-09-10	1999-09-09	Ranolazinformuleringer med langvarig frigivelse
DK99968627T DK1109558T3 (da)	1998-09-10	1999-09-09	Ranolazinformuleringer med langvarig frigivelse

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK99948196T DK1096937T3 (da)	1998-09-10	1999-09-09	Ranolazinformuleringer med langvarig frigivelse

Country Status (33)

Country	Link
US (14)	US6303607B1 (es)
EP (3)	EP1527779A1 (es)
JP (2)	JP3745621B2 (es)
KR (1)	KR100475759B1 (es)
CN (2)	CN1211086C (es)
AR (3)	AR022085A1 (es)
AT (2)	ATE285774T1 (es)
AU (4)	AU744071B2 (es)
BR (2)	BR9913553A (es)
CA (2)	CA2343376C (es)
CY (1)	CY2008020I2 (es)
CZ (2)	CZ301341B6 (es)
DE (3)	DE69922964T2 (es)
DK (2)	DK1096937T3 (es)
ES (2)	ES2177346T3 (es)
FR (1)	FR09C0001I2 (es)
GE (1)	GEP20053420B (es)
HK (2)	HK1040060A1 (es)
HU (2)	HUP0104088A3 (es)
IL (6)	IL141892A0 (es)
LU (1)	LU91504I2 (es)
MX (2)	MXPA01002598A (es)
NL (1)	NL300371I2 (es)
NO (4)	NO320986B1 (es)
NZ (2)	NZ510386A (es)
PL (3)	PL202207B1 (es)
PT (2)	PT1096937E (es)
RU (2)	RU2214233C2 (es)
SI (2)	SI1096937T1 (es)
TR (2)	TR200101262T2 (es)
TW (1)	TWI241911B (es)
UA (2)	UA67793C2 (es)
WO (2)	WO2000013686A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6479496B1 (en) *	1998-09-10	2002-11-12	Cv Therapeutics, Inc.	Methods for treating angina with ranolazine
US6303607B1 (en) *	1998-09-10	2001-10-16	Cv Therapeutics, Inc.	Method for administering a sustained release ranolanolazine formulation
US6528511B2 (en)	2000-02-18	2003-03-04	Cv Therapeutics, Inc.	Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20020052377A1 (en) *	2000-07-21	2002-05-02	Wolff Andrew A.	Method for treating angina
AU2001211213A1 (en) *	2000-10-20	2002-04-29	Galephar M/F	Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) *	2001-10-09	2004-04-16	Flamel Tech Sa	Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) *	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030220344A1 (en) *	2002-04-04	2003-11-27	Luiz Belardinelli	Method of treating arrhythmias
US20080109040A1 (en) *	2002-04-04	2008-05-08	Luiz Belardinelli	Method of treating arrhythmias
PT1492531E (pt) *	2002-04-09	2008-12-10	Flamel Tech Sa	Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permite a libertação modificada de amoxicilina
ATE419840T1 (de)	2002-04-09	2009-01-15	Flamel Tech Sa	Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US8822473B2 (en) *	2002-05-21	2014-09-02	Gilead Sciences, Inc.	Method of treating diabetes
US20040063717A1 (en) *	2002-05-21	2004-04-01	Andrew Wolff	Method of treating diabetes
GB0403098D0 (en)	2004-02-12	2004-03-17	Euro Celtique Sa	Extrusion
TWI350762B (en)	2004-02-12	2011-10-21	Euro Celtique Sa	Particulates
US20060177502A1 (en) *	2005-01-06	2006-08-10	Srikonda Sastry	Sustained release pharmaceutical formulations
FR2886150B1 (fr) *	2005-05-24	2007-08-24	Flamel Technologies Sa	Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
JP2009502957A (ja) *	2005-07-28	2009-01-29	スパーナスファーマシューティカルズインコーポレイテッド	機械的特性の向上した徐放性錠剤配合物
US20090091253A1 (en) *	2006-03-17	2009-04-09	Konica Minolta Holdings, Inc.	Organic electroluminescent element, display device and lighting device
FI20060501L (fi) *	2006-05-22	2007-11-23	Biohit Oyj	Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20090312340A1 (en) *	2007-02-13	2009-12-17	Whedy Wang	Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) *	2007-02-13	2008-08-21	Cv Therapeutics, Inc.	Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) *	2007-02-13	2010-05-27	ギリアード・パロ・アルト・インコーポレイテッド	非冠微小血管疾患の処置のためのラノラジンの使用
US20090111826A1 (en) *	2007-02-13	2009-04-30	Louis Lange	Use of ranolazine for the treatment of cardiovascular diseases
US20080214556A1 (en) *	2007-02-13	2008-09-04	Markus Jerling	Use of ranolazine for the treatment of cardiovascular diseases
ATE509015T1 (de) *	2007-03-07	2011-05-15	Concert Pharmaceuticals Inc	Deuterierte piperazinderivate als verbindungen gegen angina
WO2008116083A1 (en) *	2007-03-22	2008-09-25	Cv Therapeutics, Inc.	Use of ranolazine for elevated brain-type natriuretic peptide
EP2170333B1 (en) *	2007-05-31	2013-02-20	Gilead Sciences, Inc.	Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) *	2007-06-07	2011-01-05	北京本草天源药物研究院	一种雷诺嗪缓释片
CN101835761A (zh) *	2007-06-13	2010-09-15	奥斯拜客斯制药有限公司	取代的哌嗪
US20090012103A1 (en) *	2007-07-05	2009-01-08	Matthew Abelman	Substituted heterocyclic compounds
US20090076018A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched ranolazine
BRPI0908428A2 (pt) *	2008-02-06	2015-12-08	Gilead Sciences Inc	uso de ranozalina para tratar a dor.
US20100292217A1 (en) *	2009-05-14	2010-11-18	Gilead Palo Alto, Inc.	Ranolazine for the treatment of cns disorders
US8901128B2 (en)	2009-05-28	2014-12-02	Lupin Limited	Pharmaceutical compositions of ranolazine
WO2011036677A2 (en)	2009-09-25	2011-03-31	Lupin Limited	Sustained release composition of ranolazine
TWI508726B (zh)	2009-12-21	2015-11-21	Gilead Sciences Inc	治療心房纖維性顫動之方法
TW201215392A (en)	2010-06-16	2012-04-16	Gilead Sciences Inc	Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es)	2011-05-11	2013-07-19	Ratiopharm Gmbh	Composición de liberación modificada que comprende ranolazina
NO3175985T3 (es)	2011-07-01	2018-04-28
WO2013043925A1 (en)	2011-09-21	2013-03-28	Gilead Sciences, Inc.	Sodium channel blockers reduce glucagon secretion
US20160305924A1 (en) *	2013-04-26	2016-10-20	Laguna Pharmaceuticals , Inc.	Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
CN104758265B (zh) *	2014-01-07	2019-05-17	四川海思科制药有限公司	一种雷诺嗪缓释片药物组合物及其制备方法
TW201618783A (zh)	2014-08-07	2016-06-01	艾森塔製藥公司	以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201717919A (zh) *	2015-07-02	2017-06-01	國際藥品股份公司	雷諾多重壓縮錠劑
WO2018001582A1 (en)	2016-06-30	2018-01-04	Interquim, S.A.	Ranolazine multiple compressed tablets
AR110252A1 (es)	2016-11-30	2019-03-13	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) *	2017-06-01	2021-01-26	Sun Pharmaceutical Industries Limited	Extended release multiparticulates of ranolazine
CN112438955A (zh) *	2019-08-30	2021-03-05	深圳翰宇药业股份有限公司	一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja)	2019-12-16	2023-02-24	テナックス・セラピューティクス，インコーポレイテッド	駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) *	2019-12-17	2020-03-24	卓和药业集团有限公司	一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) *	2021-12-16	2022-11-28	Φαρματεν Α.Β.Ε.Ε.,	Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) *	2022-06-07	2023-07-20	Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια,	Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4567264A (en)	1983-05-18	1986-01-28	Syntex (U.S.A.) Inc.	Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) *	1986-01-30	1987-08-31	Syntex Inc	Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ES2182863T3 (es) *	1989-06-23	2003-03-16	Syntex Llc	Ranolazina y piperazinas relacionadas para proteger musculos esqueleticos.
US5527545A (en)	1989-09-18	1996-06-18	Recordati S.A. Chemical And Pharmaceutical Company	Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) *	1990-01-10	1993-05-11	Syntex (U.S.A.) Inc.	Long acting calcium channel blocker composition
JP2516524B2 (ja) *	1992-04-27	1996-07-24	大洋薬品工業株式会社	持続性製剤
JPH06199657A (ja) *	1992-12-10	1994-07-19	Sumitomo Pharmaceut Co Ltd	徐放性製剤
US5455045A (en)	1993-05-13	1995-10-03	Syntex (U.S.A.) Inc.	High dose formulations
JPH07112932A (ja) *	1993-08-27	1995-05-02	Mitsui Toatsu Chem Inc	徐放性医薬製剤
US5525606A (en) *	1994-08-01	1996-06-11	The United States Of America As Represented By The Department Of Health And Human Services	Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) *	1995-01-24	1996-10-08	Mitsui Toatsu Chem Inc	持効性医薬製剤
JPH08310946A (ja) *	1995-05-19	1996-11-26	Yuutoku Yakuhin Kogyo Kk	経皮吸収製剤
JPH09188617A (ja) *	1996-01-08	1997-07-22	Pola Chem Ind Inc	徐放性医薬組成物
US6479496B1 (en) *	1998-09-10	2002-11-12	Cv Therapeutics, Inc.	Methods for treating angina with ranolazine
US6303607B1 (en) *	1998-09-10	2001-10-16	Cv Therapeutics, Inc.	Method for administering a sustained release ranolanolazine formulation

1999
- 1999-05-27 US US09/321,522 patent/US6303607B1/en not_active Expired - Lifetime
- 1999-09-09 MX MXPA01002598A patent/MXPA01002598A/es active IP Right Grant
- 1999-09-09 AU AU60364/99A patent/AU744071B2/en not_active Revoked
- 1999-09-09 IL IL14189299A patent/IL141892A0/xx active IP Right Grant
- 1999-09-09 HU HU0104088A patent/HUP0104088A3/hu unknown
- 1999-09-09 CN CNB998108359A patent/CN1211086C/zh not_active Expired - Lifetime
- 1999-09-09 EP EP04030151A patent/EP1527779A1/en not_active Withdrawn
- 1999-09-09 CZ CZ20010880A patent/CZ301341B6/cs not_active IP Right Cessation
- 1999-09-09 CA CA002343376A patent/CA2343376C/en not_active Expired - Lifetime
- 1999-09-09 DE DE69922964T patent/DE69922964T2/de not_active Expired - Lifetime
- 1999-09-09 HU HU0103844A patent/HU224215B1/hu active Protection Beyond IP Right Term
- 1999-09-09 DK DK99948196T patent/DK1096937T3/da active
- 1999-09-09 WO PCT/US1999/020967 patent/WO2000013686A2/en active IP Right Grant
- 1999-09-09 PL PL381164A patent/PL202207B1/pl unknown
- 1999-09-09 CZ CZ20010879A patent/CZ301375B6/cs not_active IP Right Cessation
- 1999-09-09 ES ES99968627T patent/ES2177346T3/es not_active Expired - Lifetime
- 1999-09-09 GE GE4322A patent/GEP20053420B/en unknown
- 1999-09-09 UA UA2001031623A patent/UA67793C2/uk unknown
- 1999-09-09 PT PT99948196T patent/PT1096937E/pt unknown
- 1999-09-09 WO PCT/US1999/020968 patent/WO2000013687A2/en active Application Filing
- 1999-09-09 MX MXPA01002599A patent/MXPA01002599A/es active IP Right Grant
- 1999-09-09 CA CA002342390A patent/CA2342390C/en not_active Expired - Lifetime
- 1999-09-09 CN CNB998108367A patent/CN1193757C/zh not_active Expired - Lifetime
- 1999-09-09 SI SI9930749T patent/SI1096937T1/xx unknown
- 1999-09-09 RU RU2001109431/14A patent/RU2214233C2/ru active Protection Beyond IP Right Term
- 1999-09-09 PT PT99968627T patent/PT1109558E/pt unknown
- 1999-09-09 TR TR2001/01262T patent/TR200101262T2/xx unknown
- 1999-09-09 IL IL14189399A patent/IL141893A0/xx active IP Right Grant
- 1999-09-09 DE DE122008000065C patent/DE122008000065I1/de active Pending
- 1999-09-09 SI SI9930078T patent/SI1109558T1/xx unknown
- 1999-09-09 PL PL347073A patent/PL196668B1/pl unknown
- 1999-09-09 TR TR2001/01261T patent/TR200101261T2/xx unknown
- 1999-09-09 AT AT99948196T patent/ATE285774T1/de active
- 1999-09-09 DE DE69901570T patent/DE69901570T2/de not_active Expired - Lifetime
- 1999-09-09 ES ES99948196T patent/ES2234302T3/es not_active Expired - Lifetime
- 1999-09-09 EP EP99948196A patent/EP1096937B9/en not_active Expired - Lifetime
- 1999-09-09 EP EP99968627A patent/EP1109558B1/en not_active Expired - Lifetime
- 1999-09-09 DK DK99968627T patent/DK1109558T3/da active
- 1999-09-09 RU RU2001109432/14A patent/RU2207856C2/ru active
- 1999-09-09 BR BR9913553-1A patent/BR9913553A/pt not_active Application Discontinuation
- 1999-09-09 KR KR10-2001-7003126A patent/KR100475759B1/ko not_active IP Right Cessation
- 1999-09-09 PL PL348249A patent/PL196263B1/pl unknown
- 1999-09-09 AT AT99968627T patent/ATE217794T1/de active
- 1999-09-09 AU AU61425/99A patent/AU760435B2/en not_active Revoked
- 1999-09-09 JP JP2000568494A patent/JP3745621B2/ja not_active Expired - Lifetime
- 1999-09-09 BR BR9913626-0A patent/BR9913626A/pt not_active Application Discontinuation
- 1999-09-09 NZ NZ510386A patent/NZ510386A/en not_active IP Right Cessation
- 1999-09-09 AR ARP990104545A patent/AR022085A1/es active IP Right Grant
- 1999-09-09 UA UA2001031622A patent/UA75027C2/uk unknown
- 1999-09-09 NZ NZ510384A patent/NZ510384A/xx not_active IP Right Cessation
2000
- 2000-03-29 US US09/538,337 patent/US6369062B1/en not_active Expired - Lifetime
- 2000-05-30 TW TW088115657A patent/TWI241911B/zh not_active IP Right Cessation
2001
- 2001-03-07 IL IL141892A patent/IL141892A/en not_active IP Right Cessation
- 2001-03-07 IL IL141893A patent/IL141893A/en not_active IP Right Cessation
- 2001-03-08 NO NO20011192A patent/NO320986B1/no not_active IP Right Cessation
- 2001-03-08 NO NO20011191A patent/NO319434B1/no not_active IP Right Cessation
- 2001-08-09 US US09/925,871 patent/US6525057B2/en not_active Expired - Lifetime
- 2001-10-19 US US10/041,521 patent/US6503911B2/en not_active Expired - Lifetime
2002
- 2002-03-08 HK HK02101777A patent/HK1040060A1/xx not_active IP Right Cessation
- 2002-08-10 HK HK02105856.0A patent/HK1044284B/zh not_active IP Right Cessation
- 2002-09-25 US US10/254,707 patent/US6562826B1/en not_active Expired - Lifetime
- 2002-09-27 US US10/259,143 patent/US6617328B2/en not_active Expired - Lifetime
- 2002-09-27 US US10/256,993 patent/US6620814B2/en not_active Expired - Lifetime
2003
- 2003-03-05 US US10/382,266 patent/US6852724B2/en not_active Expired - Lifetime
- 2003-07-07 US US10/614,460 patent/US6864258B2/en not_active Expired - Lifetime
- 2003-07-07 US US10/614,420 patent/US20040097514A1/en not_active Abandoned
2004
- 2004-10-21 US US10/969,891 patent/US20050059667A1/en not_active Abandoned
2005
- 2005-01-06 US US11/031,220 patent/US20050153982A1/en not_active Abandoned
- 2005-09-07 US US11/221,450 patent/US20060147521A1/en not_active Abandoned
- 2005-09-20 NO NO20054324A patent/NO20054324L/no unknown
- 2005-10-11 JP JP2005296674A patent/JP2006096757A/ja active Pending
- 2005-11-02 US US11/265,536 patent/US20060217397A1/en not_active Abandoned
2006
- 2006-02-24 AR ARP060100700A patent/AR052921A1/es not_active Application Discontinuation
- 2006-02-24 AR ARP060100699A patent/AR053440A2/es not_active Application Discontinuation
- 2006-05-01 IL IL175371A patent/IL175371A0/en unknown
2007
- 2007-01-22 IL IL180864A patent/IL180864A0/en unknown
2008
- 2008-09-03 AU AU2008207707A patent/AU2008207707A1/en active Pending
- 2008-09-03 AU AU2008207703A patent/AU2008207703A1/en active Pending
- 2008-11-27 NL NL300371C patent/NL300371I2/nl unknown
- 2008-12-03 LU LU91504C patent/LU91504I2/fr unknown
- 2008-12-30 CY CY2008020C patent/CY2008020I2/el unknown
2009
- 2009-01-05 FR FR09C0001C patent/FR09C0001I2/fr active Active
- 2009-03-05 NO NO2009005C patent/NO2009005I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2006096757A (ja)	2006-04-13
US6864258B2 (en)	2005-03-08
DE69922964D1 (de)	2005-02-03
AU760435B2 (en)	2003-05-15
CZ2001880A3 (cs)	2001-08-15
NL300371I1 (nl)	2009-02-02
DE69922964T2 (de)	2005-12-08
HK1040060A1 (en)	2002-05-24
KR100475759B1 (ko)	2005-03-10
AU6036499A (en)	2000-03-27
ES2234302T3 (es)	2005-06-16
IL141892A0 (en)	2002-03-10
US20030099705A1 (en)	2003-05-29
CN1211086C (zh)	2005-07-20
DE69901570D1 (de)	2002-06-27
HUP0104088A3 (en)	2002-12-28
IL180864A0 (en)	2007-07-04
DK1096937T3 (da)	2005-05-09
CA2342390C (en)	2006-08-29
UA75027C2 (uk)	2006-03-15
JP2002524416A (ja)	2002-08-06
HK1044284B (zh)	2005-07-15
US6303607B1 (en)	2001-10-16
DE69901570T2 (de)	2003-01-09
SI1096937T1 (en)	2005-04-30
MXPA01002598A (es)	2002-04-08
CY2008020I1 (el)	2010-07-28
CN1193757C (zh)	2005-03-23
CA2343376A1 (en)	2000-03-16
NO319434B1 (no)	2005-08-15
PT1109558E (pt)	2002-10-31
IL141892A (en)	2006-08-20
TR200101261T2 (tr)	2002-05-21
CA2342390A1 (en)	2000-03-16
EP1096937B9 (en)	2007-02-28
PL347073A1 (en)	2002-03-11
WO2000013686A2 (en)	2000-03-16
WO2000013686A3 (en)	2000-07-06
LU91504I9 (es)	2019-01-02
NZ510384A (en)	2002-10-25
NO320986B1 (no)	2006-02-20
US6525057B2 (en)	2003-02-25
US20030100566A1 (en)	2003-05-29
CZ301375B6 (cs)	2010-02-03
US20020090396A1 (en)	2002-07-11
JP3745621B2 (ja)	2006-02-15
FR09C0001I1 (es)	2009-02-27
FR09C0001I2 (es)	2009-12-18
BR9913553A (pt)	2001-10-23
US20050059667A1 (en)	2005-03-17
MXPA01002599A (es)	2005-02-17
PL196668B1 (pl)	2008-01-31
ATE217794T1 (de)	2002-06-15
US20030166659A1 (en)	2003-09-04
CZ301341B6 (cs)	2010-01-20
US6617328B2 (en)	2003-09-09
NO20011191L (no)	2001-04-30
AU2008207707A1 (en)	2008-09-25
PT1096937E (pt)	2005-04-29
TWI241911B (en)	2005-10-21
CZ2001879A3 (cs)	2001-08-15
EP1527779A1 (en)	2005-05-04
NZ510386A (en)	2003-08-29
US20020004506A1 (en)	2002-01-10
HU224215B1 (hu)	2005-06-28
US20040029890A1 (en)	2004-02-12
EP1109558B1 (en)	2002-05-22
WO2000013687A2 (en)	2000-03-16
EP1096937A2 (en)	2001-05-09
BR9913626A (pt)	2001-12-04
LU91504I2 (fr)	2009-02-03
US20060217397A1 (en)	2006-09-28
PL202207B1 (pl)	2009-06-30
HUP0103844A3 (en)	2002-11-28
ES2177346T3 (es)	2002-12-01
AR053440A2 (es)	2007-05-09
GEP20053420B (en)	2005-01-25
US20040097514A1 (en)	2004-05-20
RU2207856C2 (ru)	2003-07-10
NO20011191D0 (no)	2001-03-08
AU6142599A (en)	2000-03-27
US20060147521A1 (en)	2006-07-06
CN1321088A (zh)	2001-11-07
US20050153982A1 (en)	2005-07-14
HUP0104088A2 (hu)	2002-05-29
AR022085A1 (es)	2002-09-04
US6620814B2 (en)	2003-09-16
CA2343376C (en)	2007-01-09
UA67793C2 (uk)	2004-07-15
IL141893A (en)	2008-08-07
RU2214233C2 (ru)	2003-10-20
AR052921A1 (es)	2007-04-11
HK1044284A1 (en)	2002-10-18
NO2009005I1 (no)	2009-03-16
NO20054324L (no)	2001-04-30
IL141893A0 (en)	2002-03-10
EP1109558A2 (en)	2001-06-27
CN1354665A (zh)	2002-06-19
US6562826B1 (en)	2003-05-13
WO2000013687A3 (en)	2000-06-29
US6852724B2 (en)	2005-02-08
ATE285774T1 (de)	2005-01-15
PL348249A1 (en)	2002-05-20
CY2008020I2 (el)	2010-07-28
PL196263B1 (pl)	2007-12-31
SI1109558T1 (en)	2002-10-31
DE122008000065I1 (de)	2009-04-09
NL300371I2 (nl)	2009-10-01
AU744071B2 (en)	2002-02-14
KR20010089874A (ko)	2001-10-12
TR200101262T2 (tr)	2001-12-21
NO2009005I2 (es)	2010-06-28
IL175371A0 (en)	2006-09-05
US6369062B1 (en)	2002-04-09
HUP0103844A2 (hu)	2002-04-29
US6503911B2 (en)	2003-01-07
EP1096937B1 (en)	2004-12-29
AU2008207703A1 (en)	2008-09-25
NO20011192D0 (no)	2001-03-08
NO20011192L (no)	2001-04-30

Publication	Publication Date	Title
DK1096937T3 (da)	2005-05-09	Ranolazinformuleringer med langvarig frigivelse
IS5555A (is)	2000-06-30	Selekoxib lyfjablöndur
ID30031A (id)	2001-11-01	Formulasi-formulasi agrokimia
ID23546A (id)	2000-05-04	Formulasi-formulasi ziprasidon
NO20004240D0 (no)	2000-08-24	Formuleringer
NO20024270D0 (no)	2002-09-06	Vedvarende frigivelsesranolazinformuleringer
ATE224703T1 (de)	2002-10-15	Brauseformulierungen
PT1130966E (pt)	2005-04-29	Formulacoes antiparasitarias
FI973816A0 (fi)	1997-09-26	Polypropen med hoeg smaeltstyrka
DK0973527T3 (da)	2003-11-24	Clarithromycinformuleringer med forlænget frigivelse
MA24473A1 (fr)	1998-10-01	Formulations
ATE227074T1 (de)	2002-11-15	Mikrokapsel-formulierungen
ATE259590T1 (de)	2004-03-15	Pour-on formulierungen
NO20002126D0 (no)	2000-04-26	Formulering med forlenget frigjøring
IS6398A (is)	2002-05-27	Lyfjablöndur
ATE232683T1 (de)	2003-03-15	Mikrokapsel-formulierungen
ATE268116T1 (de)	2004-06-15	Mesotrion-formulierungen
FI980856A0 (fi)	1998-04-17	Andningsskydd utrustad med en identifierare
NO982244D0 (no)	1998-05-15	Skumformuleringer
FI980596A0 (fi)	1998-03-18	Koerljussystem med blaendskyddsanordning